A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
about
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Tim-3 and its role in regulating anti-tumor immunity.Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.Downregulation of T cell immunoglobulin and mucin protein 3 in the pathogenesis of intracranial aneurysm.Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.Biomarkers for post-transplantation outcomes.Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.
P2860
Q33809599-4DCF84EC-E23D-4FB6-9E47-C038EB85AD48Q33909020-C8B1FA77-76D1-46B3-B55C-CD22F370B9FBQ35108289-0F94569D-648B-4368-98B5-7155819BE18FQ35487768-6341B048-0003-4B2E-B900-6B564F14E79BQ35820356-B375B99F-0844-4439-B1F0-1EB7014B40A3Q36727862-A0D10AB1-3BF7-4CC0-B1FE-E2555F0EC4DAQ36904560-EC251A14-0697-4304-BF1B-83E34C2183B6Q37585022-103D9745-F687-45AD-9271-F631AD5633A9Q38800455-265FBA21-C42A-446D-90E0-8F4C69721F45Q38829335-27D403FD-9F50-4DCF-9020-A369B93CE22DQ42182946-F0B2FFB0-2899-4F47-AB31-1DCDDB5310C3Q51028682-27CCFACB-8D7C-46CD-B4A2-D018828B9BC2Q52603913-5F1F3AD9-638D-4D69-AD13-4D6494DD7226Q54211996-CD007FCA-1E24-428E-82F6-531952E757DAQ55285607-0CDACF62-12BA-4206-9CEF-F6A7EA2FF1BF
P2860
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@en
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@nl
type
label
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@en
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@nl
prefLabel
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@en
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@nl
P2093
P2860
P1476
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
@en
P2093
Alice Chin
Bryan M Grogan
Chee-Hong Wong
Chris Baik
George B McDonald
John A Hansen
Laura Tabellini
Melissa Johnson
Paul J Martin
Qing Zhang
P2860
P304
P356
10.1016/J.BBMT.2013.06.011
P577
2013-06-17T00:00:00Z